Guggul Commiphora wightii (Arn.) Bhandari
Also called: Commiphora mukul (synonym), guggulu, mukul, Indian bdellium
Guggul is the gum resin of Commiphora wightii, used in Ayurveda. The source plant is Critically Endangered on the IUCN Red List, and its extracts and powder have been in CITES Appendix II since March 2026.
- Category
- Botanical
- Part used
- Gum resin and resin extracts (e.g., guggulipid)
- Strongest evidence
- C Limited
- Native range
- Native to Oman, southern Pakistan and northwestern and western India (POWO: "Oman, S. Pakistan to NW. & W. India")
- Reviewed
- 2026-10-29
Class 1 Well studied in people. A 2021 meta-analysis (Medicina) pooled 7 placebo-controlled RCTs (8 trial arms, 380 participants) of guggulu alone for cholesterol; trials of a garlic-guggulu combination were analyzed separately. [2]
Fact-checked 2026-10-29 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
CHeart and blood vessels3 topics
CSeveral areas, whole body or blood1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Blood cholesterol in adults with high cholesterol (US trial) | C | In a US RCT (103 adults, 8 weeks), guggulipid raised LDL-C by 4-5% while it fell 5% on placebo, with no significant change in other lipids. [1] |
| Blood cholesterol (pooled trials) | C | A 2021 meta-analysis of Ayurvedic herbs reported that guggulu lowered total cholesterol by 16.78 mg/dL and LDL by 18.78 mg/dL; this conflicts with the US trial. [2] |
| Cholesterol with a guggulu-Triphala combination | C | A 3-month RCT in 90 adults found no advantage over placebo for total or LDL cholesterol, BMI or waist circumference. [3] |
| Acne, arthritis, hemorrhoids, urinary disorders and weight loss | C | MSK states that evidence is lacking to support these uses. [4] |
Main constituents: Guggulsterones, the purported bioactive compounds, antagonists of two nuclear hormone receptors involved in cholesterol metabolism [1]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Standard-dose (1,000 mg) or high-dose (2,000 mg) guggulipid standardized to 2.5% guggulsterones, given orally 3 times daily for 8 weeks. [1]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)See details
No LiverTox chapter found. MSK cites case reports of severe liver-enzyme elevation (product with guggulsterol and red yeast rice) and acute liver failure (product with …
Details and sources - Pregnancy and breastfeedingNothing found
No published information found in the sources checked.
Details and sources - Interactions with medicines1 listed
CYP3A4 substrates
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notificationsNone on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsNone found
No published information found in the sources checked.
Details and sources
- Hypersensitivity rash developed in 6 participants on guggulipid versus none on placebo in an 8-week trial of 103 adults. [1]
- Hypersensitivity rash developed in 2 of 46 participants on guggulu-Triphala versus none on placebo in a 3-month trial. [3]
- Other reported effects: headache, mild nausea, belching, hiccups and loose stools. Case reports include contact dermatitis from creams, severe liver-enzyme elevation with a guggulsterol and red yeast rice product, and liver failure with a multi-ingredient product containing usnic acid. [4]
- MSK lists elevated TSH, T3 and T4 among herb-lab interactions. [4]
Interactions
| With | What happens |
|---|---|
| CYP3A4 substrates | Lab studies suggest guggul induces CYP3A4 and may make drugs metabolized by this enzyme less effective. [4] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Identity, quality and standardization
- The trial extract (guggulipid) was standardized to 2.5% guggulsterones. [1]
Regulatory status
- International trade: CITES Appendix II since 5 March 2026 (CoP20), covering extracts (including resins, gums and essential oils) and powder, except packaged finished retail products such as tablets and capsules. [5]
- India bans commercial export of wild-taken specimens of CITES-listed species (except cultivated plants), per CITES Notification 2018/031. [5]
- US: FDA states that, by law, it does not approve dietary supplements or their labeling; under DSHEA it has no authority to approve them before they are marketed, and firms are responsible for their products' safety and labeling. [6]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Guggulsterones Steroids [P1]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- No NDI notification naming guggul (Commiphora wightii / C. mukul) was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P2]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- No IARC or NTP carcinogenicity evaluation of guggul (Commiphora wightii) was found (IARC Monographs list of classifications and NTP technical reports checked 2026-10-29). [P3]
Liver (NIH LiverTox)
- No LiverTox chapter found. MSK cites case reports of severe liver-enzyme elevation (product with guggulsterol and red yeast rice) and acute liver failure (product with usnic acid, green tea and guggul); usnic acid was considered the main cause in the latter. [P4]
Interactions with medicines
- CYP3A4 substrates: Lab studies suggest guggul induces CYP3A4 and may make drugs metabolized by this enzyme less effective. [P4]
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity test or examination of each dietary-ingredient component before use — 21 CFR 111.75(a)(1)(i) requires at least one appropriate identity test or examination unless FDA grants an exemption petition under 111.75(a)(1)(ii). [P5]
- Guggulsterone assay — The extract tested in the controlled trial was standardized to 2.5% guggulsterones. [P1]
Supply and conservation
- IUCN Red List: Critically Endangered (CR), via GBIF species API, retrieved 2026-10-29 [P6]
- CITES Appendix II (effective 5 March 2026, CoP20) for extracts and powder, except packaged finished retail products. [P7]
- India bans commercial export of wild-taken specimens of CITES-listed species, except cultivated plants (CITES Notification 2018/031). [P7]
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- No published information found in the sources checked.
Pregnancy and breastfeeding
- No published information found in the sources checked.
Sources for this profile
- Szapary PO, et al. Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. JAMA 2003;290(6):765-772 (PMID 12915429), 2003-08-13. pubmed.ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs on the Identification of Carcinogenic Hazards to Humans. List of Classifications (checked 2026-10-29), 2026-10-29. monographs.iarc.who.int
- Memorial Sloan Kettering Cancer Center. About Herbs: Guggul (last updated January 5, 2022), 2022-01-05. mskcc.org
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (current text, checked 2026-10-29), 2026-10-29. ecfr.gov
- GBIF species API: IUCN Red List category for Commiphora wightii, 2026-10-29. api.gbif.org
- CITES / UNEP-WCMC Species+ database: Commiphora wightii, CITES listing and trade suspensions (retrieved 2026-10-29), 2026-10-29. speciesplus.net
Sources
- Szapary PO, et al. Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. JAMA 2003;290(6):765-772 (PMID 12915429), 2003-08-13. pubmed.ncbi.nlm.nih.gov
- Gyawali D, et al. A systematic review and meta-analysis of Ayurvedic herbal preparations for hypercholesterolemia. Medicina (Kaunas) 2021;57(6):546 (PMID 34071454), 2021-05-28. pubmed.ncbi.nlm.nih.gov
- Donato F, et al. Guggulu and Triphala for the treatment of hypercholesterolaemia: a placebo-controlled, double-blind, randomised trial. Complement Med Res 2021;28(3):216-225 (PMID 33242870), 2021. pubmed.ncbi.nlm.nih.gov
- Memorial Sloan Kettering Cancer Center. About Herbs: Guggul (last updated January 5, 2022), 2022-01-05. mskcc.org
- CITES / UNEP-WCMC Species+ database: Commiphora wightii, CITES listing and trade suspensions (retrieved 2026-10-29), 2026-10-29. speciesplus.net
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- Plants of the World Online (POWO), Royal Botanic Gardens, Kew; WCVP data. Commiphora wightii (Arn.) Bhandari (accessed 2026-10-29), 2026-10-29. powo.science.kew.org
- WCVP via GBIF species API: Commiphora mukul (Hook. ex Stocks) Engl., synonym of Commiphora wightii (Arn.) Bhandari (retrieved 2026-10-29), 2026-10-29. api.gbif.org
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.